Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine

Vaccine

Volumn 24, Issue 15, 2006, Pages 2843-2849

  Hepburn, M J ^a,b   Kortepeter, M G ^a   Pittman, P R ^a   Boudreau, E F ^a   Mangiafico, J A ^a   Buck, P A ^a   Norris, S L ^a   Anderson, E L ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b Box 84 ^*  (United States)

Author keywords

Booster; Neutralizing antibody; Yellow fever vaccine

Indexed keywords

NEUTRALIZING ANTIBODY; YELLOW FEVER VACCINE;

ANTIBODY RESPONSE; DEMOGRAPHY; HUMAN; LABORATORY PERSONNEL; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW; SEROLOGY; STATISTICAL ANALYSIS; VACCINATION;

EID: 33644923779     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.12.055     Document Type: Article

References (26)

1. S.E. Robertson, B.P. Hull, O. Tomori, O. Bele, J.W. LeDuc, and K. Esteves Yellow fever: a decade of reemergence JAMA 276 14 1996 1157 1162
2. T.P. Monath, R. Nichols, W.T. Archambault, L. Moore, R. Marchesani, and J. Tian Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial Am J Trop Med Hyg 66 5 2002 533 541
3. A.D. Barrett, and T.P. Monath Epidemiology and ecology of yellow fever virus Adv Virus Res 61 2003 291 315
4. F. Guirakhoo, K. Pugachev, Z. Zhang, G. Myers, I. Levenbook, and K. Draper Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates J Virol 78 9 2004 4761 4775
5. J. Arroyo, C.A. Miller, J. Catalan, and T.P. Monath Yellow fever vector live-virus vaccines: West Nile virus vaccine development Trends Mol Med 7 8 2001 350 354
6. L.E. Markowitz, P. Albrecht, W.A. Orenstein, S.M. Lett, T.J. Pugliese, and D. Farrell Persistence of measles antibody after revaccination J Infect Dis 166 1 1992 205 208
7. H. Groot, and R.B. Riberiro Neutralizing haemagglutination-inhibiting antibodies to yellow fever 17 years after vaccination with 17D vaccine Bull World Health Organ 27 1962 699 707
8. J.D. Poland, C.H. Calisher, T.P. Monath, W.G. Downs, and K. Murphy Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine Bull World Health Organ 59 6 1981 895 900
9. M. Martin, L.H. Weld, T.F. Tsai, G.T. Mootrey, R.T. Chen, and M. Niu Advanced age a risk factor for illness temporally associated with yellow fever vaccination Emerg Infect Dis 7 6 2001 945 951
10. S. Kitchener Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX Vaccine 22 17-18 2004 2103 2105
11. T.P. Monath, K. McCarthy, P. Bedford, C.T. Johnson, R. Nichols, and S. Yoksan Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections Vaccine 20 7-8 2002 1004 1018
12. C.L. Wisseman Jr., and B.H. Sweet Immunological studies with group B arthropod-borne viruses. III. Response of human subjects to revaccination with 17D strain yellow fever vaccine Am J Trop Med Hyg 11 1962 570 575
13. C.E. Smith, L.H. Turner, and P. Armitage Yellow fever vaccination in Malaya by subcutaneous injection and multiple puncture. Neutralizing antibody responses in persons with and without pre-existing antibody to related viruses Bull World Health Organ 27 1962 717 727
14. R.M. Wong-Chew, J.A. Beeler, S. Audet, and J.I. Santos Cellular and humoral immune responses to measles in immune adults re-immunized with measles vaccine J Med Virol 70 2 2003 276 280
15. W.H. Bancroft, F.H. Top Jr., K.H. Eckels, J.H. Anderson Jr., J.M. McCown, and P.K. Russell Dengue-2 vaccine: virological, immunological, and clinical responses of six yellow fever-immune recipients Infect Immun. 31 2 1981 698 703
16. J.A. Mangiafico, J.L. Sanchez, L.T. Figueredo, J.W. LeDuc, and C.J. Peters Isolation of a newly recognized Bunyawera serogroup virus from a febrile human in Panama Am J Trop Med Hyg 39 1988 593 596
17. D.J. McClain, P.L. Summers, S.A. Harrison, A.L. Schmaljohn, and C.S. Schmaljohn Clinical evaluation of a vaccinia-vectored Hantaan virus vaccine J Med Virol 60 1 2000 77 85
18. B. Reinhardt, R. Jaspert, M. Niedrig, C. Kostner, and J. L'Age-Stehr Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection J Med Virol 56 2 1998 159 167
19. T.P. Monath, and M.S. Cetron Prevention of yellow fever in persons traveling to the tropics Clin Infect Dis 34 10 2002 1369 1378
20. B. Christenson, and M. Bottiger Measles antibody: comparison of long-term vaccination titres, early vaccination titres and naturally acquired immunity to and booster effects on the measles virus Vaccine 12 2 1994 129 133
21. J.S. Kaufman, and R.S. Cooper Commentary: considerations for use of racial/ethnic classification in etiologic research Am J Epidemiol 154 4 2001 291 298
22. D.R. Williams Race and health: basic questions, emerging directions Ann Epidemiol 7 5 1997 322 333
23. R. Witzig The medicalization of race: scientific legitimization of a flawed social construct Ann Intern Med 125 8 1996 675 679
24. T.P. Monath, R.B. Craven, D.J. Muth, C.J. Trautt, C.H. Calisher, and S.A. Fitzgerald Limitations of the complement-fixation test for distinguishing naturally acquired from vaccine-induced yellow fever infection in flavivirus-hyperendemic areas Am J Trop Med Hyg 29 4 1980 624 634
25. C.L. Wisseman Jr., B.H. Sweet, M. Kitaoka, and T. Tamiya Immunological studies with group B arthropod-borne viruses. I. Broadened neutralizing antibody spectrum induced by strain 17D yellow fever vaccine in human subjects previously infected with Japanese encephalitis virus Am J Trop Med Hyg 11 1962 550 561
26. C.H. Calisher, N. Karabatsos, J.M. Dalrymple, R.E. Shope, J.S. Porterfield, and E.G. Westaway Antigenic relationships between flaviviruses as determined by cross-neutralization tests with polyclonal antisera J Gen Virol 70 Pt 1 1989 37 43